We are pleased to announce that our COO, Kate Rochlin, PhD, will participate in a panel discussion next week, September 24th, at the BioProcess International: Cell & Gene Therapy Manufacturing & Commercialization US Meeting in Boston, MA. $INAB #CancerZero #Biotech

Our CEO, William Ho, shares his journey from finance to founding IN8bio. Discover how a chance encounter during a 2015 blizzard led to our efforts to transform cancer therapy and achieve #CancerZero with #GammaDeltaTCells! $INAB #Biotech #CancerResearch #Entrepreneurship

Did you miss IN8bio's webcast this morning? No worries! You can catch the replay on our website. Click here to listen: edge.media-server.com/mmc/p/hfqtxc7q/ $INAB #CancerZero #IN8bio

#NEWS: Today, we are pleased to report our second quarter 2024 financial results and company updates. Read the press release for full details: bit.ly/4dg9bG7 $INAB #IN8bio #biotech #CancerZero #GDTcells

Our CEO, William Ho, shares the heartfelt story behind our CSO, Dr. Lamb's experience with six young #leukemia patients in the 1990s and our focus on #GammaDeltaTCells. Learn about our innovative DeltEx platform and our goal to achieve #CancerZero! $INAB #Biotech #CancerResearch

Some of our New York @IN8bio  team members had a blast attending yesterday's New York Yankees vs. New York Mets baseball game for the #SubwaySeries, and of course, we had to rock our #CancerZero and IN8bio gear! #NYYvsMETS #YankeesvsMets #LGM #RepBX

CEO & co-founder William Ho explains IN8bio's mission to achieve Cancer Zero by completely and safely eliminating all tumor cells. Discover more about IN8bio's innovative gamma-delta T cell therapies and groundbreaking approach. $INAB #CancerZero #IN8bio #Biotech @whoinNY

IN8bio’s CEO and co-founder, William Ho, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference tomorrow, Tuesday, June 25th, at 2:30 pm EST. Read more here: bit.ly/3xws7kc $INAB #CancerZero H.C. Wainwright & Co.

Our CEO, William Ho, shares an exciting update from our Phase 1 INB-100 study at #EHA2024. Compared with the historical 50%, 100% of leukemia patients treated with our #GammaDeltaTcells achieved one-year relapse-free survival. Stay tuned for more updates! $INAB #CancerZero

#NEWS: IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Read today’s press release: bit.ly/3XpmSNZ $INAB #ASCO24 #CellTherapy #CancerZero #GBM #BrainCancer #glioma

IN8bio is pleased to announce an upcoming poster presentation on our INB-200 autologous gamma-delta T cell Phase 1 #GBM dose-escalation study at the 2024 ASCO annual meeting on June 1st. Read more here: bit.ly/3yuUXBN #ASCO24 $INAB  #CellTherapy #CancerZero #GDTcells

#NEWS: @IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at #ASGCT2024 presented by Mariska ter Haak. Read more here: bit.ly/3wAam30 ASGCT $INAB #CellTherapy #CancerZero #GDTcells

#NEWS: Today, we are pleased to report our first quarter 2024 financial results and company updates. Read the press release for full details: bit.ly/3WzkELt #IN8bio #biotech #CancerZero #GDTcells $INAB

#NEWS: IN8bio is excited to announce an Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (#ASGCT2024) Annual Meeting on May 10th at 3:45 pm ET. Read more here: bit.ly/44g6ZdT ASGCT $INAB #CellTherapy #CancerZero

Why are we combining gamma-delta T cells with #chemotherapy? Immune cells can’t rapidly destroy tumor cells all by themselves. We’re leveraging both benefits to achieve our goal of #CancerZero. Hear from @IN8bio’s Chief Medical Officer, Trishna Goswami, MD, in today’s video.

Our COO, Kate Rochlin, PhD, had the pleasure of speaking at the Beakers & Brews event hosted by Birmingham Business Alliance. It's an honor for @IN8bio to contribute to Birmingham's robust and growing #biotech scene! We hope you all continue to join us on our mission of #CancerZero. Learn